Research
Hormonal
Semaglutide 2.4 mg weekly reduces major adverse cardiovascular events (MACE) by 20% in people with BMI ≥27 kg/m² and pre-existing cardiovascular disease, independent of diabetes status.
If you are overweight (BMI 27+) and have heart disease, ask your doctor about semaglutide. It has been shown to reduce the risk of heart attack, stroke, or death from heart causes by 20%. This benefit exists even if you don't have diabetes.
StrongSupportsVERY_HIGH confidence
This trial is important in being the first RCT of an obesity treatment to show a reduction in major adverse cardiovascular events (MACE). In over 17,500 people with BMI (cid:1)27 kg/m2 and pre-existing cardiovascular disease, treatment with semaglutide led to a 20% reduction (hazard ratio, 0.80; 95% CI 0.72 to 0.90; P < 0.001) in a composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke
Why this rating
Based on SELECT trial, N>17,500, long duration (40 months).
Source
Obesity medications: A narrative review of current and emerging agents
Qi Q et al. · Osteoarthritis and Cartilage Open · 2024
narrative_reviewCited 20×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →